Pharma shares were in focus on September 24 after fresh approvals.

Sun Pharma and Dr. Reddy’s gained as new USFDA clearances were announced.

Lupin also received approval for a key generic drug in the U.S. market.

Brokerages expect these launches to support revenue growth in FY26.

The sector has been resilient amid global health demand stability.

Export orders from regulated markets gave a boost to earnings outlook.

Domestic demand for medicines also stayed strong during the quarter.

The Nifty Pharma index rose more than 1 percent in intraday trade.

Analysts expect pharma stocks to see steady gains in coming months.

Overall, the sector is regaining traction among long-term investors.